What is PT‑141 (bremelanotide)?
PT‑141, the generic name bremelanotide, is a melanocortin‑4 receptor (MC4R) agonist that works centrally (in the brain) to influence sexual desire and arousal pathways. It is distinct from PDE‑5 inhibitors (e.g., sildenafil), which act on penile blood flow and are not indicated for women.
In the United States, bremelanotide (brand: Vyleesi) is FDA‑approved for premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD). It is taken “as needed” by subcutaneous injection before anticipated sexual activity. In Australia, bremelanotide is not on the ARTG and can only be accessed as an unapproved medicine via a prescriber (see Access in Australia).
What the evidence shows for low libido in women
Two Phase 3, randomised, double‑blind, placebo‑controlled trials in premenopausal women with acquired, generalised HSDD evaluated bremelanotide over 24 weeks (often called the RECONNECT studies).
- Primary outcomes included changes in the FSFI‑Desire domain (FSFI‑D) and sexual distress (FSDS‑DAO).
- Across trials, bremelanotide produced modest but statistically significant improvements versus placebo.
Quantitative outcomes reported in the FDA label and trial publications indicate approximately:
- FSFI‑Desire: mean improvement about 0.2–0.3 points greater than placebo (24‑week endpoint).
- FSDS‑DAO (distress): mean reduction about 0.3–0.4 points greater than placebo.
- Responder rates (meeting pre‑specified thresholds on both desire and distress): absolute differences typically around 8–12% versus placebo, translating to a number‑needed‑to‑treat (NNT) roughly 9–13.
- Satisfying sexual events were not consistently improved versus placebo in the pivotal program.
Sources: FDA Vyleesi label and Phase 3 publications (FDA label; Phase 3 trials (RECONNECT)).
Takeaway: PT‑141 can help a subset of appropriately selected premenopausal women with HSDD, but average effects are modest. A careful biopsychosocial assessment is essential before considering medication.
Who it may and may not be for
- Most studied in premenopausal women with acquired, generalised HSDD (not lifelong, not situation‑specific).
- Not studied adequately in postmenopausal women and not indicated in men (see separate pages for men and ED).
- HSDD secondary to relationship conflict, untreated mental health conditions, medication effects (e.g., SSRIs), or hormonal issues requires addressing those causes first.
Helpful starting points:
- ISSWSH clinical guidance on HSDD assessment and management (ISSWSH guidelines).
- Australian women’s health resources (Jean Hailes on libido; RANZCOG women’s health).
How PT‑141 is taken (per FDA label)
- Dose: 1.75 mg subcutaneous injection (abdomen or thigh) at least 45 minutes before anticipated sexual activity.
- Do not use more than 1 dose within 24 hours.
- Do not use more than 8 doses per month.
- If there is no improvement after 8 weeks of use, discontinue and re‑evaluate.
Source: FDA Vyleesi prescribing information.
Safety guardrails and common side effects
Label‑based cautions to protect safety:
- Transient increases in blood pressure and reductions in heart rate can occur after dosing; avoid in uncontrolled hypertension or known cardiovascular disease.
- Nausea is common (often early and can be severe); some discontinue because of it. Other reactions include flushing, headache, injection‑site reactions, and focal hyperpigmentation (including on gums and skin) which may be persistent.
- Pregnancy and breastfeeding: not recommended; adequate human data are lacking. Use effective contraception and avoid if pregnant or trying to conceive.
- Discontinue if no clinically meaningful benefit after 8 weeks of as‑needed use.
Source: FDA Vyleesi label.
Drug interactions and timing with other medicines
- Gastric emptying: Bremelanotide can delay gastric emptying and reduce exposure to some oral medicines.
- Oral naltrexone: Exposure may be significantly reduced; avoid co‑administration or consider non‑oral alternatives under clinician supervision.
- Practical tip: If you take essential oral medicines in the evening, discuss timing (e.g., taking them well before PT‑141 or using alternative routes) with your prescriber.
Source: FDA label interaction section.
Access in Australia: SAS Category B and Authorised Prescriber
Bremelanotide is not registered on the ARTG. Legal access requires a medical prescriber to use the TGA’s unapproved medicine pathways.
Two main pathways
- Special Access Scheme (SAS) Category B – Your doctor submits a clinical justification to the TGA for you as an individual, obtains informed consent, and, if approved, arranges supply through a pharmacy or sponsor. See TGA guidance: SAS Category B.
- Authorised Prescriber (AP) – A doctor obtains approval to prescribe a specific unapproved medicine for a defined patient group without lodging individual SAS B applications each time. See: Authorised Prescriber scheme.
Typical steps
- Consult a GP/specialist experienced in sexual health to confirm HSDD and rule out common contributors (medications, hormonal, psychological, relationship factors).
- Discuss benefits/risks and label limits; provide consent.
- Prescriber lodges SAS B or uses AP approval; prescription issued if appropriate.
- Supply is arranged via a compliant pharmacy or sponsor/importer; ongoing follow‑up and adverse event monitoring occur.
Personal importation cautions
- Importing prescription medicines without meeting TGA Personal Importation Scheme (PIS) rules can lead to seizure and penalties.
- PIS requires an Australian prescription and strict quantity limits; it does not override state and schedule controls. See: TGA Personal Importation Scheme.
- Report adverse events to the TGA: Report a side effect.
Alternatives and complementary approaches
- Address contributors: medication review (e.g., SSRIs), mood/sleep, pelvic pain, hormonal issues, relationship/psychosexual factors.
- Non‑pharmacological supports: sex therapy, couples therapy, stress management, targeted education (see Jean Hailes resources).
- Other pharmacological options: flibanserin (different profile; daily dosing, alcohol warnings) and off‑label approaches in selected cases under specialist care (see ISSWSH guidance).
Quick answers to common questions
How fast does PT‑141 work?
Most people dose at least 45 minutes before anticipated sexual activity. Some report onset within 45–90 minutes; responses vary.
Can I use it with alcohol?
The bremelanotide label does not include an alcohol contraindication (unlike flibanserin), but alcohol can worsen nausea and dizziness in some people. Use caution and discuss with your clinician.
Can I use it while on antidepressants?
Some antidepressants reduce libido. Your clinician should first review whether the antidepressant can be adjusted. If PT‑141 is still considered, monitor closely for benefit and side effects.
Is skin darkening permanent?
Focal hyperpigmentation (including gums and skin) has been reported and may persist in some cases. Stop and seek review if you notice pigment changes.
How often can I use it?
No more than one dose in 24 hours and no more than eight doses per month. If no meaningful benefit after about eight weeks of use, discontinue and reassess.
Key references
- Vyleesi (bremelanotide) US Prescribing Information (FDA label): accessdata.fda.gov
- RECONNECT Phase 3 Trials in Premenopausal Women with HSDD: PubMed 31135765
- ISSWSH Clinical Practice Guidance (HSDD): isswsh.org
- TGA Special Access Scheme (SAS): tga.gov.au
- TGA Authorised Prescriber Scheme: tga.gov.au
- TGA Personal Importation Scheme: tga.gov.au
- Report adverse events in Australia: tga.gov.au
- RANZCOG women’s health resources: ranzcog.edu.au
- Jean Hailes – Libido and sexual wellbeing: jeanhailes.org.au
Get help: ask a clinician about PT‑141 and low libido
Send us a few details and we’ll connect you with a qualified prescriber to discuss whether PT‑141 is appropriate, alternatives to consider, and how SAS/AP access works in Australia.
Your details are handled in line with Australian privacy principles. We do not sell personal data.
Bottom line
For premenopausal women with carefully diagnosed HSDD, PT‑141 (bremelanotide) can provide modest improvements in desire and distress for some, with predictable side effects and strict label limits on dosing. Because causes of low libido are often multifactorial, the best results come from a holistic assessment and a shared decision with a clinician who understands women’s sexual health and Australia’s SAS/AP pathways.